San Diego-dependent Viking Therapeutics marked itself as a serious competitor within the weight loss drug sector in February immediately after revealing promising facts from the mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the compa